摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-1,2r,4,5t-tetramethyl-piperazine | 697728-90-8

中文名称
——
中文别名
——
英文名称
(+/-)-1,2r,4,5t-tetramethyl-piperazine
英文别名
(+/-)-1,2r,4,5t-Tetramethyl-piperazin;(2R,5S)-1,2,4,5-tetramethylpiperazine
(+/-)-1,2<i>r</i>,4,5<i>t</i>-tetramethyl-piperazine化学式
CAS
697728-90-8
化学式
C8H18N2
mdl
——
分子量
142.244
InChiKey
ZKZVTFXTQPDVLR-OCAPTIKFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    6.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
    申请人:FOULON Loic
    公开号:US20110059955A1
    公开(公告)日:2011-03-10
    The present invention relates to novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, to their preparation and to their therapeutic application. The compounds of the present invention correspond to the formula (I): in which the variables are as set forth in the specification. These compounds exhibit a strong affinity and a high selectivity for human arginine-vasopressin (AVP) V 1a receptors and some compounds additionally exhibit a strong affinity for AVP V 1b receptors.
    本发明涉及新颖的3-氨基烷基-1,3-二氢-2H-吲哚-2-酮衍生物,其制备以及其治疗应用。本发明的化合物对应于式(I): 其中变量如规范中所述。这些化合物表现出对人类精氨酸加压素(AVP)V1a受体具有强亲和力和高选择性,而且一些化合物还表现出对AVP V1b受体具有强亲和力。
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    申请人:Li Hui
    公开号:US20100190770A1
    公开(公告)日:2010-07-29
    Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
    公开了化合物I的结构,含有这些化合物的组合物,以及在治疗需要调节JAK途径或抑制JAK激酶,特别是JAK 2和JAK3的情况下使用这些化合物和组合物的方法。
  • NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS
    申请人:BARONI Marco
    公开号:US20120245149A1
    公开(公告)日:2012-09-27
    The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyI)-1-alkanone derivatives of formula (I): wherein A, W, R2 and n are as defined in the disclosure, to the method of preparation thereof and the therapeutic use thereof.
    该公开涉及到式(I)的(杂环融合哌啶)-(哌嗪基)-1-烷酮衍生物和(杂环融合吡咯啉)-(哌嗪基)-1-烷酮衍生物: 其中A、W、R2和n如公开所定义,以及其制备方法和治疗用途。
  • NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS
    申请人:BARONI Marco
    公开号:US20120245150A1
    公开(公告)日:2012-09-27
    The disclosure relates to (heterocycle-tetrahydropyridine)(piperazinyl)-1-alkanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alkanone derivatives of formula (I): wherein A, B, m, n, W, and R2 are as defined in the disclosure; to the methods of preparing said derivatives, and to the therapeutic uses thereof.
    该披露涉及到公式(I)中的(杂环-四氢吡啶基)(哌嗪基)-1-烷酮和(杂环-二氢吡咯烷基)(哌嗪基)-1-烷酮衍生物;其中A、B、m、n、W和R2如所述定义;以及制备上述衍生物的方法和其治疗用途。
  • Derivative having ppar agonistic activity
    申请人:Itai Akiko
    公开号:US20090286974A1
    公开(公告)日:2009-11-19
    A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y 1 is a bond or —NR 6 — or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y 2 Z 1 - is a group of the formula: R 7 are each independently hydrogen, optionally substituted lower alkyl or the like, R 8 and R 9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z 1 is a bond, —O—, —S— or —NR 9 —, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y 3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, optionally substituted lower alkenylene or the like, and Z 2 is COOR 3 or the like.
    化合物的公式(I):其药物可接受的盐或溶剂,其中环Q是可选择的取代的单环芳基,可选择的取代的单环杂芳基,可选择的融合芳基或可选择的融合杂芳基,Y1是键或-NR6-或类似物,环A是可选择的取代的非芳香杂环二基,公式组:-Y2Z1-是公式组:R7各自独立地是氢,可选择的取代的低烷基或类似物,R8和R9各自独立地是氢或可选择的取代的低烷基,n是1到3之间的整数,Z1是键,-O-,-S-或-NR9-,环B是可选择的取代的芳香碳杂环二基或可选择的取代的芳香杂环二基,Y3是键,可选择的取代的低烷基,可选择地介入-O-,可选择的取代的低烯基或类似物,并且Z2是COOR3或类似物。
查看更多